Rapid Resolution of Pulmonary Alveolar Proteinosis in MARS1 Deficiency: Role of Methionine Supplementation

Background: Methionyl-tRNA synthetase (MARS1) deficiency is a rare autosomal recessive disorder characterized by multisystem involvement, including pulmonary alveolar proteinosis (PAP), anemia, liver dysfunction, and exocrine pancreatic insufficiency. Treatment is challenging in ventilator-dependent infants, with methionine supplementation emerging as a targeted option.

Case Presentation: We report a 6-month-old female infant born preterm who presented with severe respiratory failure requiring prolonged ventilation, tracheostomy, and oxygen support. She had recurrent infections, failure to thrive, cirrhosis, exocrine pancreatic insufficiency, and hypoalbuminemia. High-resolution Chest CT and Bronchoalveolar lavage (BAL) confirmed PAP. Whole exome sequencing (WES) revealed homozygosity for two previously reported MARS1 variants (p.Ala393Thr and p.Ser567Leu).

Intervention and Outcome: Following high-dose oral methionine (60-120 mg/kg/day) titrated to keep methionine at the higher therapeutic range, the patient demonstrated marked clinical improvement. Segmental BAL was used as a temporizing, safer alternative to whole lung lavage. Within four weeks, she showed marked improvement in respiratory status, weight gain, albumin levels, and liver functions. She was discharged home with tracheostomy, ventilator, and oxygen therapy but no further need for lavage procedure.

Conclusion: This is the first reported case with MARS-1-related PAP from the Arabian Gulf successfully managed with methionine supplementation. It underscores the importance of early genetic evaluation and targeted metabolic therapy in managing critically ill infants with this rare condition.